CytomX’s Varsetatug Masetecan continues to demonstrate positive data supporting potential as a new treatment option in late-line colorectal cancer

CAR-T Digest - August 2020

Weekly Digest - March 2026

16 March 2026: CytomX’s Varsetatug Masetecan continues to demonstrate positive data supporting potential as a new treatment option in late-line colorectal cancer

CytomX Therapeutics has strengthened its position in next-generation ADCs, reporting encouraging Phase 1 expansion data for Varsetatug Masetecan (Varseta-M), an EpCAM-targeting PROBODY ADC, in patients with late-line metastatic colorectal cancer (CRC)
In this context, varsetatug masetecan (Varseta-M) demonstrated encouraging efficacy, with confirmed response rates reaching up to 32% and median progression-free survival of approximately 7 months at optimized dosing levels, indicating potential improvement over existing late-line treatment standards
Importantly, these benefits were accompanied by a manageable safety profile, with most adverse events being low grade and key toxicities like diarrhea showing improved control through optimized prophylactic strategies
This progress is particularly meaningful given the dire landscape of colorectal cancer in heavily pretreated patients, where limited options and poor prognosis highlight a clear unmet need for more effective therapies
Building on these results, CytomX is now preparing for regulatory discussions with the U.S. Food and Drug Administration to define a potential registrational path, while also advancing combination studies, positioning Varseta-M as a promising future option in the treatment landscape of advanced CRC